[1] |
WANG Zhiqing, LIU Xiyu, FAN Lei.
Advances and controversies in the adjuvant treatment of early breast cancer
[J]. China Oncology, 2025, 35(3): 255-262.
|
[2] |
WANG Xiaobo, WANG Tao.
Current status and future perspectives on consensus and controversies in advanced breast cancer for 2024
[J]. China Oncology, 2025, 35(3): 263-272.
|
[3] |
LI Bin, TAO Zhonghua, HU Xichun.
Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era
[J]. China Oncology, 2025, 35(3): 273-282.
|
[4] |
WU Chunxiao, PANG Yi, GU Kai, YAN Jiaying, WANG Chunfang, XIANG Yongmei, SHI Yan.
Survival analysis of female breast cancer in Shanghai: a population-based study from 2002 to 2017
[J]. China Oncology, 2025, 35(3): 291-297.
|
[5] |
ZHAO Kaile, WANG Lei, GENG Jianxiong, CUI Chengwei, YU Yan.
Research status and prospects of treatment for malignant pleural mesothelioma
[J]. China Oncology, 2025, 35(3): 326-332.
|
[6] |
AN Tianqi, TIAN Jianhui, ZHOU Yiyang, LUO Bin, QUE Zujun, LIU Yao, YU Pan, ZHAO Ruihua, YANG Yun.
Research progress on treatment of pleural effusion related to immune checkpoint inhibitors
[J]. China Oncology, 2025, 35(3): 333-338.
|
[7] |
LU Yufeng, WANG Han, XIE Yifan, JIANG Yizhou, SHAO Zhimin.
Significant fundamental translational research on breast cancer in China: progress and prospects
[J]. China Oncology, 2025, 35(2): 143-153.
|
[8] |
LIN Jialin, WANG Wenna, XU Binghe.
Current status and future perspectives of antibody-drug conjugates in breast cancer therapy
[J]. China Oncology, 2025, 35(2): 154-166.
|
[9] |
YANG Xin, SHI Qianfeng, LIU Qiang.
Progress of important clinical research on breast cancer in China in 2024
[J]. China Oncology, 2025, 35(2): 167-175.
|
[10] |
LI Xing, PENG Ziqi, YU Xinmiao, JIN Feng.
Important research progress in clinical practice for early breast cancer in 2024
[J]. China Oncology, 2025, 35(2): 176-185.
|
[11] |
WU Song, YUAN Yang, JIANG Zefei.
Important clinical studies that changed the clinical practice of advanced breast cancer in 2024
[J]. China Oncology, 2025, 35(2): 186-194.
|
[12] |
ZENG Cheng, WANG Yuanyi, WANG Jiani, MA Fei.
Advances in immune checkpoint inhibitor therapy for breast cancer: research progress and future directions
[J]. China Oncology, 2025, 35(2): 195-204.
|
[13] |
LI Junjie.
Progress and future prospects in local and systemic treatment of early breast cancer
[J]. China Oncology, 2025, 35(2): 205-212.
|
[14] |
WANG Qing, YU Yushuai, WANG Chenxi, JIANG Zirong, LI Jialu, TANG Shicong, SONG Chuangui.
Current status and prospects of tertiary lymphoid structure heterogeneity in predicting response to neoadjuvant therapy and characterizing immune microenvironment in triple-negative breast cancer
[J]. China Oncology, 2025, 35(2): 213-218.
|
[15] |
LAN Yu, WANG Fenghua.
Comparison and review of updated guidelines for advanced gastric cancer diagnosis and treatment in 2024: CSCO, NCCN and ESMO
[J]. China Oncology, 2025, 35(2): 219-227.
|